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ABSTRACT
Objective: To better understand the estrogen (E2) agonist action of triiodothyronine (T3) the 
effects of these hormones on ER negative MDA-MB-231 breast cancer cells were compared with 
those on S30, a clone of MDA-MB-231 stably transfected with ERα cDNA, in terms of proliferation 
and modulation of hormone receptors. Results: Growth experiments showed that MDA-MB-231 
was not modulated by any hormone or tamoxifen (TAM). Treatment with E2, 10-8M or 10-9M had 
little effect on S30 proliferation. T3 at 10-8M significantly inhibited proliferation. This effect was not 
reverted by TAM. Treatments with 10-8M concentration of E2 or T3 reduced ERα gene expression 
in S30, an effect partially blocked by association with TAM, with no effect on TR expression. These 
results suggest that, in S30, 10-8M T3 has a similar action to E2 relative to ERα gene modulation. 
Conclusions: Such results emphasize the need of determining T3 levels, before the introduction 
of antiestrogenic forms of treatment in breast cancer patients. Arq Bras Endocrinol Metab. 2009;53(7):859-64.
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RESUMO
Objetivo: Para compreender melhor a ação da triiodotironina (T3) agonista de estrógeno (E2), 
foram comparados os efeitos destes hormônios em células de câncer de mama MDA-MB-231 
ER negativas com um clone de MDA-MB-231, transfectado estavelmente com o cDNA de ERα 
(S30), em termos de proliferação e modulação dos receptores hormonais. Resultados: Experi-
mentos de crescimento mostraram que MDA-MB-231 não foi modulada por qualquer hormônio 
ou pelo tamoxifeno (TAM). O crescimento de S30 foi essencialmente inalterado por tratamento 
com E2 10-9M ou 10-8M, mas T3 10-8M inibiu significativamente a proliferação quando compara-
da a ambas concentrações de E2. Esse efeito não foi revertido pelo TAM, sugerindo um resul-
tado não genômico, independente de ERE. Tratamentos com 10-8M de E2 ou de T3 reduziram a 
expressão do gene ERα em S30, efeito parcialmente impedido pela associação com TAM, sem 
efeito na expressão de TR. Os resultados sugerem que, em S30, T3 10-8M  tem ação semelhante 
ao E2 com relação à modulação do gene ERα. Conclusões: Esses resultados enfatizam a ne-
cessidade de dosagem de T3 circulante antes da introdução do tratamento antiestrogênico no 
câncer de mama. Arq Bras Endocrinol Metab. 2009;53(7):859-64.
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INTRODUCTION
Estrogens are pivotal in the growth of both nor-mal and neoplastic mammary tissues, and mediate 
most of their actions via ligand-dependent transcription 
factors, known as estrogen receptors (ER) (1,2). The 
involvement of thyroid hormone (TH) in the develo-
pment and differentiation of normal breast tissue has 
been established (3-5). Although epidemiologic and 
experimental studies have associated TH pathologies 
with an increase in the risk of breast cancer, the role 
of these hormones remains controversial. Kapdy and 
Wolfe (6) and Mustacchi and Greenspan (7) found an 
association between TH ingestion and increase in the 
risk of mammary cancer. On the other hand, Vorherr 
(8) described an increase in the survival of hyperthyroid 
patients with breast cancer. Saraiva and cols. (9) suggest 
the existence of a biological link between breast can-
cer in post-menopausal woman and subclinical hyper-
thyroidism. Turken and cols. (10) and Gogas and cols. 
(11) reported an increase in the prevalence of thyroid 
autoimmune disease in patients with breast cancer. 
Cristofanilli and cols. (12) showed that spontaneous 
clinical hypothyroidism may decrease the aggressive-
ness of breast cancer and reduce tumor incidence. 
Most, if not all, major triiodothyronine (T3) actions 
are mediated by specific high affinity nuclear receptors 
(TR), which are encoded by two genes, TRα and TRβ 
(13). Recent results reveal substantial changes in the 
expression profile of TH receptors, suggesting a possi-
ble deregulation that could trigger breast cancer deve-
lopment (14).
In a previous work (15), we demonstrated in MCF-
7 cells, an ER-positive breast cancer cell line, that T3 
mimicked the effects of estradiol (E2), stimulating 
growth, modulating mRNA transcription of growth 
factors and inducing the expression and activity of E2-
inducible proteins. In addition, these T3 effects were 
antagonized by the simultaneous addition of tamoxifen 
(TAM), which is a competitive inhibitor of E2 binding 
to ER. Similar effects, however, were not observed in 
the ER-negative MDA-MB-231 breast cancer cells, in 
spite of the presence of high TR amounts, suggesting 
that, in MCF-7 cells, both ligands share a common sig-
naling pathway via ER. In addition, Dinda and cols. 
(16) indicated that in T47D breast cancer cells also ER 
positive, T3 regulates T47D cell cycle progression and 
proliferation raising the p53 level and causing hyper-
phosphorylation of pRb by a common mechanism in-
volving ER and T3 receptor (T3R)-mediated pathways. 
In line with these results, a physiological concentration 
of L-thyroxine (T4) has been recently reported to in-
duce MCF-7 cells proliferation measured by tritiated 
thymidine or appearance of proliferating cell nuclear 
antigen (PCNA) (17). 
Jeng and cols. (18) demonstrated previously that 
after the stable transfection of ERα in MDA-MB-231 
cells (devoid of ERα and ERβ) with an ERα vector 
(S30), these ER negative cells regained hormonal res-
ponsiveness.
With the objective of clarifying the E2 agonist ac-
tion of T3, we herein compared the effects of E2 and 
T3 in terms of proliferation and modulation of ER and 
TR in two breast cancer cell lines: MDA-MB-231, whi-
ch is estrogen-insensitive, but possesses TRα and TRβ, 
and S30 cell, that is a MDA-MB-231 transfected with 
wild ERα (19).
METHODS
Cell culture and growth experiments
Cell growth was assessed by using two methods: WST-1 
(Roche Diagnostics, Mannheim, Germany) – indirect 
method, a colorimetric assay based on the cleavage of 
the tetrazolium salt WST-1 by mitochondrial deshydro-
genases in viable cells; and cell count – direct method, 
using a Neubauer chamber and trypan blue staining 
(Sigma, St Louis, MO, USA). Both experiments were 
performed in parallel and made in quadruplicates.
MDA-MB-231 and MCF-7 cells were grown in 
RPMI 1640 medium supplemented with 1.2 g/L 
NaHCO3, 10 nM Hepes pH 7.4, and 10% fetal bovine 
serum (FBS). S30 cells were kindly provided by Dr. VC 
Jordan (Northwestern University, Chicago, IL) and 
were grown in minimal essential medium (MEM) wi-
thout phenol red, with Earle’s Salts and 25 mM Hepes, 
supplemented with 1% antibiotic antimycotic solution, 
200 nM L-glutamine, 10 nM non-essential amino acids 
(NEAA), 5% FBS, 6 ng/mL bovine insulin, and 500 
μg/mL G418. Both cells were kept at 37 °C in humi-
dified 5% CO2 and air. The medium was changed every 
two days. Before starting hormone treatments, the 
medium was replaced by phenol red-free medium to 
eliminate all known sources of estrogen, and FBS was 
replaced by 5% charcoal-stripped FBS. After 24 hours 
(day 0), media were changed and hormones added in 
absolute ethanol, with daily media changes. The free 
hormone levels were further measured directly in the 
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media by radioimmunoassay and the expected hormo-
ne concentrations were detected. 
WST-1
The media were changed and hormones added dissol-
ved in absolute ethanol after 24 hours (day 0), with 
daily media changes. Two hours before the readings of 
absorbance Spectra Max 190 (Molecular Devices) at a 
wavelength of 450 nm, 10 µL WST-1 was added to 
each well to determine proliferation and cell viability. 
The same procedure was followed for seven days. 
Cell count
The media were changed and hormones added dissol-
ved in absolute ethanol after 24 hours (day 0), with 
daily media changes. Cells were harvested in triplicate 
at the indicated times and cell numbers were counted. 
Cell numbers were plotted as a logarithmic function 
against time and cell population doubling time (DT) 
was estimated at the exponential phase.
Semi-quantitative reverse transcription-polymerase 
chain reaction analyses of mRNA for ERα, PR, TRα 
and TRβ
Total RNA was extracted from cells by TRIzol Reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA) 
which is based on the guanidine thiocyanate method. 
Frozen cells were mechanically homogenized on ice in 
1 mL of ice-cold TRIzol. Total RNA was solubilized in 
Rnase-free H2O and quantified by measuring the opti-
cal density (OD) at 260 nm. RNA purity was ensured 
by obtaining a 260/280 nm OD ratio of approximately 
2.0. Two micrograms of RNA was reverse-transcribed 
with oligo dT primers and Superscript reverse trans-
criptase (RT) in a total volume of 21 µL, according to 
standard methods (Invitrogen Life Technologies, Carl-
sbad, CA, USA). Control “No RT” reactions were per-
formed by omitting the RT enzyme. These reactions 
were then polymerase chain reaction (PCR)-amplified 
to ensure that DNA did not contaminate RNA. Primer 
pairs for ERα, TRα, TRβ and PR were designed from a 
sequence published in GenBank. PCR conditions were 
as follows: cycles of 94 °C for 30 seconds, annealing of 
specific primers (Table 1) 1 minute to ERα; 30 seconds 
to PR, TRα and TRβ, 30 seconds at 72 °C for exten-
sion (except ERα, 1 minute). The bands corresponding 
to each gene were quantified by densitometry as inte-
grated optical density. PCR products were run in dupli-
cate on a different gel for each gene, and results were 
averaged. The size (then number of base pairs) of each 
band corresponded to the size of processed mRNA. 
The PCR signals were normalized by co-amplification 
(multiplex) of a human cyclophilin transcript with 0.5 
μL of each primer, except for ERα PCR, which was 
performed in simplex. Final numeric values are expres-
sed as a ratio between each and the internal (housekee-
ping) gene, human cyclophilin.
Statistical analysis
Data are expressed as mean ± sd. Two-way ANOVA 
was used to analyze cellular proliferation and receptor 
amplification. Multiple comparisons were performed 
using the Tukey's test (20). The level of significance 
was p < 0.05.
RESULTS
T3, E2 and steroidal antagonist (TAM) action on cell 
proliferation
MDA-MB-231 growth was not modulated by the addi-
tion of T3, E2 or TAM. The concentrations of E2 (10-
7M and 10-8M) were equally effective in stimulating 
MCF-7 cell proliferation. The simultaneous addition of 
TAM (10-6M) inhibited the proliferative effect of E2 
(data not shown).
Table 1. Oligonucleotide primers used for polymerase chain reaction (PCR) amplification of reverse transcribed RNA
Product
Sequence
TA (ºC) CyclesForward primer Reverse primer
ERα 5’- AAGACCGAAGAGGAGGGAGA-3’ 5’- GATGTGGGAGAGGATGAGGA - 3’ 59,8 35
PR 5’- AGCAGTTCTAGTCCCCCAGA -3’ 5’- CCTCCTCCTCAACCTCCAC - 3’ 56 35
TRα 5’- GACCCAGAGGAGAACAGTGC-3’ 5’- CACCCGCTTCGAGTCATCTA - 3’ 56 32
TRβ 5’- GAGGAGAACCGGGAGAAAAG -3’ 5’- TCTGGGTCATAGCGCACAG - 3’ 56 35
TA: annealing temperature.
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S30 growth was not modulated by E2 or TAM. Nei-
ther the treatment with two T3 concentrations, 10-10M 
and 10-9M nor the concomitant addition of TAM affec-
ted DT of S30 cells in comparison with controls. The 
concentration of T3 (10-8M) significantly increased DT 
and, therefore, significantly reduced cell proliferation 
when compared to the concentrations of E2, but this 
effect was not reversed by TAM (Figure 1).
The results of the cell proliferation experiments per-
formed in parallel were similar. Figures 1 and 2 show 
the data obtained by the cell count method. 
Figure 1. Growth experiments in S30 breast cancer cells.
S30 breast cancer cells were cultivated with MEM without phenol red, with Earle’s Salts and 25 mM 
Hepes, supplemented with 1% antibiotic antimycotic solution, 200 nM L-glutamine, 10 nM non-
essential amino acids (NEAA), 5% FBS, 6 ng/mL bovine insulin, and 500 μg/mL G418. Cells were 
seeded (2.5 x 103 cells per well) and treated for three days with estradiol 10-9M (E2 1), 10-8M (E2 2), 
10-7M (E2 3), triiodothyronine 10-10M (T3 1),  10-9M (T3 2), 10-8M  (T3 3), and tamoxifen 10-6M (TAM). 
Results are mean of 4 simultaneous experiments ± sd with * p < 0.01 (p values determined in relation 
to E2 1 and E2 2).
Figure 2. Expression of ERα, PR, TRα, TRβ with co-amplification of a human cyclophilin 
transcript in MCF-7, MDA-MB-231 (MDA) and S30 breast cancer cell lines.
Marker MCF-7 MDA S30
6.6 Kb
9.5 Kb
5.3 Kb
7 Kb
ERα
Cyclophilin
PR
Cyclophilin
TRα
Cyclophilin
TRβ
Cyclophilin
ER, progesterone and thyroid receptors 
determination in S30 cell
RT-PCR was used to detect ER, progesterone (PR) and 
thyroid receptors (TR) transcripts in order to better 
characterize our model. Both MDA-MB-231 and S30 
expressed TRα and TRβ, but not PR. Only S30 cell ex-
pressed ERα. MCF-7 cells, which express ER, PR and 
TR, were used as a positive control (Figure 2).
Effects of E2 and T3 in TRα, TRβ and ERα expression
Treatment of either MDA-MB-231 (data not shown) 
or S30 cells with T3 (10-8M) or E2 (10-8M), both in 
the absence or presence of TAM (10-6M), did not affect 
TRα and TRβ levels (data not shown). In S30 cells, 
the presence of E2 or T3 significantly decreased ERα 
expression. Association of TAM (10-6M) with either E2 
(10-8M) or T3 (10-8M) reverse partially the reduction 
of ERα expression induced by the presence of the hor-
mones alone (Figure 3).
* p < 0.05.
Figure 3. Expression of ERα (A) and TRα (B) transcript in S30 breast cancer cell 
line estimated by reverse transcription-polymerase chain reaction (RT-PCR) in each 
treated groups.
Data were run in duplicate on different gels for each gene, and the results were averaged. Quantification 
of the PCR signal was obtained by densitometric analysis of the product in integrated optical density 
(IOD). Gene expressions were normalized to the cyclophilin signal from the same RT product. 
Normalized data are expressed as means ± sd. 
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DISCUSSION
The aim of this paper was to expand our previous in-
vestigations (Nogueira and Brentani, 1996) suggesting 
that TH elicits estrogenic effects via ER. The effects 
of E2 and T3 on the proliferation and the modulation 
of ER and TR were examined in MDA-MB-231 stably 
transfected with the wild type ERα (S30) and compa-
red to the parental ER-negative MDA-MB-231 breast 
cancer cells.
In agreement with our previous results, MDA-
MB-231 growth was independent from the addition of 
E2, T3, and TAM (15). In S30 transfected cells, ER-
mRNA levels were similar to those shown by ER res-
ponsive MCF-7 cells (21). However, ER expression in 
MDA-MB-231 did not lead to significant effects on cell 
proliferation upon E2 treatment. Contrariwise several 
authors have reported that restoration of ERα expres-
sion in MDAMB-231 leads to a ligand dependent inhi-
bition of growth (22-24) an effect blocked by anties-
trogens. Moreover, Moggs and cols. (25) demonstrated 
that this antiproliferative effect of E2 in MDAMB-231 
transduced with ER is mediated by down regulation of 
many genes involved in cell cycle progression as revea-
led by a microarray approach.
We have no clear explanation for our divergent re-
sults. This abnormal behavior may be explained by the 
specific conditions of our S30 cells. According to Vig-
non and cols. (26) quiescent cells maintained in low 
serum concentrations (2%) were insensitive or slightly 
stimulated by E2 treatment. As late passages of S30 cells 
were used here, it is possible that ER had lost efficiency, 
even though its concentrations remained high, as in ER 
positive hormone-independent tumors. According to 
Garcia and cols. (22), E2 inhibitory effects are small and 
reduced the total cell content by only 30-40% after four 
to six days of treatment. They also observed that the 
maximal inhibitory effect of E2 (2 nM) was compatible 
with the occupancy of ER sites and did not increase fur-
ther with concentrations up to 1 μM. One explanation 
of our results may be related to the evident reduction 
of ERα mRNA levels after E2 treatment of S30 cells, 
leading to no significant effects on cell growth. T3 at 
10-8M concentration also reduced ERα gene expression 
in those cells as compared to controls, suggesting that 
E2 and T3 actions were similar. As the down regulation 
is partly inhibited by TAM, it seems that T3 may inte-
ract with ERE or influence pathways controlled by ERE. 
Down regulation ERα protein by E2 was previously re-
ported in MCF-7 and T47D (27), and it has been sug-
gested to be due to the degradation of ER induced by 
E2. However, unlike E2, 10-8M T3 treatment inhibited 
S30 proliferation which is the classical effect of E2 in the 
same cells. As TAM could not reverse the proliferation 
rate of S30 cells in combination with T3, these data that 
suggested that this inhibitory effect of T3 is probably 
not dependent on ERE, pointing to a non-genomic pa-
thway or resulting from different interactions with other 
promoter elements, including AP1 or SP1 (28,29). Ac-
cording to Zhou-Li and cols. (30), antiestrogens are 
non competitive inhibitors of T3 only in the cells whose 
growth is responsive to E2.
In conclusion, our results showed that the effects 
of T3 in S30 growth differ from those of E2, but both 
hormones down regulated ERα gene expression. Thus, 
in absence of E2, clinically important changes in TH 
levels could influence pathways controlled by ER.
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